Drug intelligence / Profile preview

Sinucon

Development stage
Unknown
Lead developer
Ascendis Health
Modality
Small Molecules
Administration
Oral
01

Overview

Sinucon is an over-the-counter (OTC) multi-symptom combination medication marketed by Ascendis Health (and subsequently Shanur Healthcare) primarily in South Africa. It is formulated to provide relief from sinus congestion, nasal congestion, headaches, and allergy symptoms associated with the common cold, influenza, and allergic rhinitis. The drug contains a combination of four active small molecule ingredients: the antihistamines chlorpheniramine maleate and phenyltoloxamine citrate, and the decongestants phenylephrine hydrochloride and phenylpropanolamine hydrochloride. These components work by blocking histamine H1 receptors to reduce allergic responses like sneezing and itchy eyes, and by stimulating adrenergic receptors to cause vasoconstriction in the nasal mucosa, thereby reducing swelling and congestion.

Brand names
SinuconSinucon Tablets
Other names
Sinucon Nasal Drops
02

Targets

ADRA2A (α2A)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Sinucon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinucon.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call